Lixte Biotech Hlds (LIXT) Stock Price, Quote & News

Company Profile

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab t...

Industry: Biotechnology

Sector: Healthcare

Phone: 631 830 7092

Fax: 631 982 5050

Website: lixte.com

Address:

680 East Colorado Boulevard, Suite 180, Pasadena, United States

BillionerOfKing Feb. 3 at 4:36 PM

$LIXT Current Stock Price: $3.60

0 · Reply

suspendFlow Jan. 28 at 11:01 PM

$LIXT this is ready for a run.

0 · Reply

glenn009 Jan. 23 at 3:25 AM

$ADTX Holy Grail pattern INCOMING!! 🚀💥💯 "I have spoken." $IBRX $LIXT $SAVA

1 · Reply

NetworkNewsWire Jan. 22 at 7:47 PM

$LIXT Advances a Novel Approach to Enhancing Cancer Therapy https://ibn.fm/VkeLU

0 · Reply

NetworkNewsWire Jan. 21 at 8:21 PM

BioMedNewsBreaks — $LIXT to Participate In DealFlow Discovery Conference https://ibn.fm/K3ih2

0 · Reply

NetworkNewsWire Jan. 20 at 5:57 PM

BioMedNewsBreaks — $LIXT to Participate In DealFlow Discovery Conference https://ibn.fm/K3ih2

0 · Reply

Scoty_D Jan. 15 at 7:19 PM

$LIXT Cmon you oink oink! Your due for a pumperoo!!

0 · Reply

NetworkNewsWire Jan. 13 at 7:14 PM

TinyGemsBreaks – $LIXT Engages IBN to Support Corporate Communications Strategy https://ibn.fm/LjK8H

0 · Reply

NetworkNewsWire Jan. 8 at 8:07 PM

BioMedNewsBreaks – $LIXT Expands Ovarian Cancer Trial With MD Anderson and GSK https://ibn.fm/WhSKw

0 · Reply

NetworkNewsWire Jan. 7 at 8:18 PM

$LIXT Is ‘One to Watch’ https://ibn.fm/iyXYJ

0 · Reply

DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

Jan 20, 2026, 8:00 AM EST - 15 days ago

LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

Dec 23, 2025, 8:00 AM EST - 6 weeks ago

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

Dec 8, 2025, 8:30 AM EST - 2 months ago

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities

Dec 3, 2025, 11:00 AM EST - 2 months ago

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

Dec 3, 2025, 8:00 AM EST - 2 months ago

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

Nov 25, 2025, 8:30 AM EST - 2 months ago

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

Oct 29, 2025, 8:00 AM EDT - 3 months ago

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

Oct 16, 2025, 8:00 AM EDT - 3 months ago

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Sep 16, 2025, 8:30 AM EDT - 5 months ago

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

Sep 15, 2025, 5:40 PM EDT - 5 months ago

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

Sep 10, 2025, 4:05 PM EDT - 5 months ago

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

Sep 5, 2025, 8:35 AM EDT - 5 months ago

24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor

Sep 3, 2025, 8:00 AM EDT - 5 months ago

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

Aug 27, 2025, 8:15 AM EDT - 5 months ago

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

Aug 25, 2025, 8:05 AM EDT - 5 months ago

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

Aug 19, 2025, 11:18 AM EDT - 6 months ago

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

Aug 18, 2025, 8:00 AM EDT - 6 months ago

LIXTE Biotechnology Holdings Provides Corporate Update

Aug 14, 2025, 9:06 PM EDT - 6 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Aug 14, 2025, 8:05 AM EDT - 6 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

Aug 13, 2025, 8:49 AM EDT - 6 months ago

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

Aug 13, 2025, 7:30 AM EDT - 6 months ago

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

Jul 16, 2025, 8:05 AM EDT - 7 months ago

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Jul 9, 2025, 5:15 PM EDT - 7 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

Jul 9, 2025, 8:05 AM EDT - 7 months ago

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Jul 8, 2025, 2:57 PM EDT - 7 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Jul 2, 2025, 4:05 PM EDT - 7 months ago

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Jul 1, 2025, 4:15 PM EDT - 7 months ago

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

Mar 31, 2025, 8:30 AM EDT - 11 months ago

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Mar 27, 2025, 8:30 AM EDT - 11 months ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

Feb 25, 2025, 8:30 AM EST - 1 year ago

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Feb 13, 2025, 10:35 AM EST - 1 year ago

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 11, 2025, 8:42 AM EST - 1 year ago

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 10, 2025, 5:00 PM EST - 1 year ago

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

Sep 4, 2024, 8:30 AM EDT - 1 year ago

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Aug 26, 2024, 8:30 AM EDT - 1 year ago

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Aug 19, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Provides Update On Recent Activities and Developments

Aug 15, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Aug 14, 2024, 10:50 PM EDT - 1 year ago

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Jun 14, 2024, 11:00 AM EDT - 1 year ago

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Jun 14, 2024, 9:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Jun 6, 2024, 8:30 AM EDT - 1 year ago

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Jun 3, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

May 20, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Provides Update on Recent Activities

May 8, 2024, 9:25 AM EDT - 1 year ago

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

Mar 21, 2024, 8:30 AM EDT - 2 years ago

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Feb 27, 2024, 8:30 AM EST - 2 years ago

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

Feb 26, 2024, 8:30 AM EST - 2 years ago

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Jan 29, 2024, 8:30 AM EST - 2 years ago

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

Nov 13, 2023, 8:30 AM EST - 2 years ago

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

BillionerOfKing Feb. 3 at 4:36 PM

$LIXT Current Stock Price: $3.60

0 · Reply

suspendFlow Jan. 28 at 11:01 PM

$LIXT this is ready for a run.

0 · Reply

glenn009 Jan. 23 at 3:25 AM

$ADTX Holy Grail pattern INCOMING!! 🚀💥💯 "I have spoken." $IBRX $LIXT $SAVA

1 · Reply

NetworkNewsWire Jan. 22 at 7:47 PM

$LIXT Advances a Novel Approach to Enhancing Cancer Therapy https://ibn.fm/VkeLU

0 · Reply

NetworkNewsWire Jan. 21 at 8:21 PM

BioMedNewsBreaks — $LIXT to Participate In DealFlow Discovery Conference https://ibn.fm/K3ih2

0 · Reply

NetworkNewsWire Jan. 20 at 5:57 PM

BioMedNewsBreaks — $LIXT to Participate In DealFlow Discovery Conference https://ibn.fm/K3ih2

0 · Reply

Scoty_D Jan. 15 at 7:19 PM

$LIXT Cmon you oink oink! Your due for a pumperoo!!

0 · Reply

NetworkNewsWire Jan. 13 at 7:14 PM

TinyGemsBreaks – $LIXT Engages IBN to Support Corporate Communications Strategy https://ibn.fm/LjK8H

0 · Reply

NetworkNewsWire Jan. 8 at 8:07 PM

BioMedNewsBreaks – $LIXT Expands Ovarian Cancer Trial With MD Anderson and GSK https://ibn.fm/WhSKw

0 · Reply

NetworkNewsWire Jan. 7 at 8:18 PM

$LIXT Is ‘One to Watch’ https://ibn.fm/iyXYJ

0 · Reply

NetworkNewsWire Jan. 7 at 6:12 PM

BioMedNewsBreaks — $LIXT Announces $4.3 Million Registered Direct Offering Priced at Market https://ibn.fm/UCloz

0 · Reply

SuperGreenToday Jan. 1 at 6:06 AM

$LIXT

0 · Reply

CalipersInk Dec. 26 at 5:45 PM

$LIXT Long-term holders appear to prioritize operational credibility. Efficiency initiatives must translate into measurable productivity. Missteps would reset expectations abruptly. Upside remains tied to tangible progress, not assumptions.

0 · Reply

Stock_Catcher Dec. 23 at 1:03 PM

$LIXT LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

0 · Reply

JeffreyCress Dec. 18 at 2:10 PM

$LIXT direct offering $4

1 · Reply

OpenOutcrier Dec. 18 at 2:08 PM

$LIXT (-26.8% pre) Lixte Biotechnology raises $4.3 million in registered direct offering https://ooc.bz/l/87899

0 · Reply

Scoty_D Dec. 18 at 2:00 PM

$LIXT sheeeeeet

0 · Reply

Draganafly Dec. 10 at 2:53 PM

$LIXT 9,500-Room Global Shortfall Creates Massive Opportunity for Undervalued Company That Just Acquired a $300 Million Cancer Treatment Platform. How LIXTE Biotechnology (Nasdaq: LIXT) acquisition of the revolutionary LiGHT Proton Therapy Platform could transform cancer care and deliver outsized returns for early investors.

0 · Reply

Biggio Nov. 27 at 10:01 PM

$LIXT Click here for the full snapshot: https://wallstreetnation.com/breakthrough-cancer-therapy LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)has just announced a game-changing acquisition that could transform the company from a $25 million market cap stock into something far more significant. The company has acquired Liora Technologies and its revolutionary LiGHT proton therapy platform… This platform is a breakthrough technology that has already had $300 million invested in its development…proven clinical validation at 230 MeV…and breakthrough economics that could finally make precision cancer treatment accessible to millions of patients worldwide.

0 · Reply

Market Cap	27.81M
Revenue (ttm)	0.00
Net Income (ttm)	-3.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	16,649
Avg Vol	97,290
Day's Range	N/A - N/A
Shares Out	7.48M
Stochastic %K	35%
Beta	0.94
Analysts	Strong Buy
Price Target	N/A